Roche Tries Again With Failed Huntington’s Drug Tominersen
Potential In Younger Adults
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.